Sharechat Logo

Nuplex names Holcim's Clive Cuthell as new CFO as Ian Davis retires

Tuesday 28th October 2014

Text too small?

Nuplex Industries, which last week announced the sale of two Australasian units to focus on global resins, named Holcim Australia's Clive Cuthell as chief financial officer, replacing Ian Davis.

Davis will retire at the end of the year after more than five years with the specialty chemicals company, Auckland-based Nuplex said in a statement.

"I am pleased to welcome Clive to Nuplex as we embark on the next phase of Nuplex’s journey as a dedicated global resins business," said chief executive Emery Severin.

Cuthell has been CFO at cement maker Holcim Australia for five years.

Last week Nuplex said Axieo, an investment vehicle of Sydney-based Champ Private Equity, will buy Nuplex Masterbatch, the plastic additives business, and Nuplex Specialities, the distribution business for A$127.5 million. Nuplex would use the funds to repay debt and possibly make a capital return, it said.

Shares of Nuplex fell 1.5 percent to $3.20 and have declined 4.4 percent this year.

 

 

 

 

BusinessDesk.co.nz



  General Finance Advertising    

Comments from our readers

No comments yet

Add your comment:
Your name:
Your email:
Not displayed to the public
Comment:
Comments to Sharechat go through an approval process. Comments which are defamatory, abusive or in some way deemed inappropriate will not be approved. It is allowable to use some form of non-de-plume for your name, however we recommend real email addresses are used. Comments from free email addresses such as Gmail, Yahoo, Hotmail, etc may not be approved.

Related News:

December 27th Morning Report
FBU - Fletcher Building Announces Director Appointment
December 23rd Morning Report
MWE - Suspension of Trading and Delisting
EBOS welcomes finalisation of First PWA
CVT - AMENDED: Bank covenant waiver and trading update
Gentrack Annual Report 2024
December 20th Morning Report
Rua Bioscience announces launch of new products in the UK
TEM - Appointment to the Board of Directors